Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), Drug Alcohol Depend, vol.115, issue.1-2, pp.120-150, 2011. ,
, United Nations Office on D, Crime: World Drug Report, 2015.
, United Nations Office on Drugs and Crime (UNODC), 2015.
Pharmacotherapies for cannabis dependence, Cochrane Database Syst Rev, vol.1, p.8940, 2019. ,
Psychosocial and pharmacological interventions for the treatment of cannabis use disorder, F1000Res, vol.7, p.173, 2018. ,
Pharmacological and biochemical interactions between opioids and cannabinoids ,
, Trends Pharmacol Sci, vol.20, issue.7, pp.287-94, 1999.
Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers, Neuropsychopharmacology, vol.32, issue.6, pp.1391-403, 2007. ,
Interaction between naltrexone and oral THC in heavy marijuana smokers, Psychopharmacology (Berl), vol.166, issue.1, pp.77-85, 2003. ,
Naltrexone does not attenuate the effects of intravenous ?9-tetrahydrocannabinol in healthy humans, Int J Neuropsychopharmacol, vol.15, issue.9, pp.1251-64, 2012. ,
Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers, Neuropsychopharmacology, vol.40, issue.11, pp.2489-98, 2015. ,
Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics, Exp Clin Psychopharmacol, vol.15, issue.3, pp.272-81, 2007. ,
Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: A Randomized Clinical Trial, JAMA Psychiatry, vol.73, issue.10, pp.1056-63, 2016. ,
Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents, Handb Exp Pharmacol, 2019. ,
The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal, Neuropsychopharmacology, vol.43, issue.1, pp.173-194, 2018. ,